Compare INLF & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLF | IMRN |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.0M |
| IPO Year | 2025 | N/A |
| Metric | INLF | IMRN |
|---|---|---|
| Price | $0.52 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 562.6K | ★ 1.3M |
| Earning Date | 09-29-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,332,282.00 | $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 33.11 | ★ 48.63 |
| 52 Week Low | $0.48 | $0.68 |
| 52 Week High | $21.00 | $2.48 |
| Indicator | INLF | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 25.44 |
| Support Level | $0.50 | $0.68 |
| Resistance Level | $0.54 | $0.95 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 16.86 | 30.65 |
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.